Hesperos and Psilera Partner to Use Organ-on-a-Chip Technology in Frontotemporal Dementia Drug Development

Hesperos and Psilera have announced a collaboration aimed at advancing preclinical research for treatments targeting frontotemporal dementia, a progressive neurological disorder with limited therapeutic options. The partnership will utilize Hesperos’ organ-on-a-chip platform to support the development of Psilera’s lead compound designed to address this condition.

The organ-on-a-chip technology replicates human physiological systems on microfluidic devices, enabling researchers to study disease mechanisms and evaluate drug efficacy in a controlled environment. By integrating this innovative platform into its preclinical studies, Psilera seeks to accelerate the development process for its compound while gaining deeper insights into its potential effects on frontotemporal dementia. Both companies aim to contribute to addressing the unmet medical needs associated with this challenging disorder through their combined expertise.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

Date: June 9, 2025

Related posts:

Weight Training May Slow Cognitive Decline and Protect Aging Brains FDA Approves Zevaskyn: First Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa The AIQ Imperative: A New Competitive Paradigm for BioPharma Medical Technology Advances Target 15 Million Annual Neurovascular Cases Globally

Author

Mark Chiang